Optinose announces XHANCE added to Express Scripts’ national formularies

Optinose announced that XHANCE has been added to Express Scripts’ national formularies, including the National Preferred, Flex, and Basic formularies, among the largest commercial formularies in the U.S. with more than 24 million lives. “XHANCE is approved for treatment of chronic rhinosinusitis and, importantly, is the only medication approved for by far the most common type – without nasal polyps, so we are very pleased that Express Scripts has added XHANCE as a preferred option to these formularies,” said Ramy Mahmoud, MD, MPH, CEO of Optinose. “We look forward to seeing the addition of XHANCE to these Express Scripts national formularies result in increased patient access to the only evidence-based prescription treatment for this disease.”